Acute Myeloid Leukemia (AML) Secondary Panel
Use
This FISH panel test is utilized to identify abnormalities in acute myeloid leukemia (AML) that occur with less frequency than those covered by the AML Frontline Panel. It includes analysis of MECOM rearrangement, NUP98 rearrangement, DEK::NUP214 fusion, BCR::ABL1 fusion, and TP53 (17p13) deletion. The test is frequently ordered in conjunction with the AML Frontline Panel or as a reflex test if the frontline panel is negative.
Special Instructions
While bone marrow is the specimen of choice in most heme malignancies, the test will attempt to process and report samples received greater than 72 hours post-collection. Specimens should be shipped ambient or refrigerated, but not frozen, using a refrigerated gel pack to protect from extreme temperatures.
Limitations
The test has limitations in terms of detecting only the listed rearrangements and fusions associated with AML. Specimens exposed to extreme temperatures, clotted specimens, or those with insufficient cell numbers may be rejected. Anticoagulants toxic to cells can also lead to rejection. Turnaround times are stated for clinical purposes and may vary based on biopharma protocol requirements.
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
Not provided
Container
EDTA preferred (NaHep accepted)
Storage Instructions
2°C to 25°C
Causes for Rejection
Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |